<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541694</url>
  </required_header>
  <id_info>
    <org_study_id>STA10</org_study_id>
    <nct_id>NCT03541694</nct_id>
  </id_info>
  <brief_title>Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea</brief_title>
  <official_title>Passive Enhanced Safety Surveillance of the Live Attenuated Yellow Fever Virus Vaccine Stamaril® in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The
      objective is to collect suspected related adverse events following vaccination with Stamaril®
      in routine practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This ESS replaces the routing post-marketing surveillance required after product approval in
      Korea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting suspected related adverse events</measure>
    <time_frame>Within 30 days after vaccination</time_frame>
    <description>Spontaneous reporting of suspected related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting suspected serious related adverse events</measure>
    <time_frame>Within 30 days after vaccination</time_frame>
    <description>Spontaneous reporting of serious suspected related adverse events</description>
  </secondary_outcome>
  <enrollment type="Actual">622</enrollment>
  <condition>Yellow Fever</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stamaril®</intervention_name>
    <description>Routine vaccination with Stamaril yellow fever vaccine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who have been vaccinated against yellow fever with Stamaril® vaccine in Korean
        yellow fever vaccination centers during the enhanced surveillance period.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Vaccination with Stamaril® vaccine in routine practice in Korea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Pasteur Investigational Site 001</name>
      <address>
        <city>Seoul</city>
        <zip>04564</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Yellow fever</keyword>
  <keyword>Stamaril®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yellow Fever</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

